nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—ABCB1—ovarian cancer	0.14	1	CbGaD
Regorafenib—ABCG2—Topotecan—ovarian cancer	0.0658	0.206	CbGbCtD
Regorafenib—ABCG2—Paclitaxel—ovarian cancer	0.0326	0.102	CbGbCtD
Regorafenib—ABCG2—Carboplatin—ovarian cancer	0.0307	0.0961	CbGbCtD
Regorafenib—ABCB1—Topotecan—ovarian cancer	0.0237	0.0744	CbGbCtD
Regorafenib—ABCG2—Docetaxel—ovarian cancer	0.0236	0.0738	CbGbCtD
Regorafenib—ABCG2—Doxorubicin—ovarian cancer	0.0176	0.055	CbGbCtD
Regorafenib—CYP2C8—Paclitaxel—ovarian cancer	0.0174	0.0544	CbGbCtD
Regorafenib—ABCB1—Vinorelbine—ovarian cancer	0.0167	0.0524	CbGbCtD
Regorafenib—CYP3A4—Topotecan—ovarian cancer	0.0142	0.0445	CbGbCtD
Regorafenib—CYP2B6—Doxorubicin—ovarian cancer	0.0124	0.0387	CbGbCtD
Regorafenib—CYP2C9—Paclitaxel—ovarian cancer	0.0121	0.0379	CbGbCtD
Regorafenib—ABCB1—Paclitaxel—ovarian cancer	0.0118	0.0368	CbGbCtD
Regorafenib—CYP3A4—Vinorelbine—ovarian cancer	0.01	0.0314	CbGbCtD
Regorafenib—ABCB1—Docetaxel—ovarian cancer	0.0085	0.0266	CbGbCtD
Regorafenib—CYP3A4—Paclitaxel—ovarian cancer	0.00704	0.0221	CbGbCtD
Regorafenib—ABCB1—Doxorubicin—ovarian cancer	0.00633	0.0198	CbGbCtD
Regorafenib—CYP3A4—Docetaxel—ovarian cancer	0.00509	0.0159	CbGbCtD
Regorafenib—CYP3A4—Doxorubicin—ovarian cancer	0.00379	0.0119	CbGbCtD
Regorafenib—DDR2—myometrium—ovarian cancer	0.00233	0.0167	CbGeAlD
Regorafenib—NTRK1—decidua—ovarian cancer	0.00233	0.0167	CbGeAlD
Regorafenib—DDR2—uterine cervix—ovarian cancer	0.00182	0.013	CbGeAlD
Regorafenib—DDR2—decidua—ovarian cancer	0.00173	0.0124	CbGeAlD
Regorafenib—FRK—gonad—ovarian cancer	0.0017	0.0122	CbGeAlD
Regorafenib—DDR2—endometrium—ovarian cancer	0.00164	0.0118	CbGeAlD
Regorafenib—EPHX2—myometrium—ovarian cancer	0.00158	0.0113	CbGeAlD
Regorafenib—FRK—female reproductive system—ovarian cancer	0.00152	0.0109	CbGeAlD
Regorafenib—DDR2—uterus—ovarian cancer	0.00151	0.0108	CbGeAlD
Regorafenib—NTRK1—testis—ovarian cancer	0.00148	0.0106	CbGeAlD
Regorafenib—FGFR1—myometrium—ovarian cancer	0.0014	0.01	CbGeAlD
Regorafenib—FLT4—embryo—ovarian cancer	0.00137	0.00979	CbGeAlD
Regorafenib—DDR2—female reproductive system—ovarian cancer	0.00136	0.00974	CbGeAlD
Regorafenib—MAPK11—female reproductive system—ovarian cancer	0.00129	0.00924	CbGeAlD
Regorafenib—DDR2—female gonad—ovarian cancer	0.00124	0.00886	CbGeAlD
Regorafenib—DDR2—vagina—ovarian cancer	0.00123	0.00881	CbGeAlD
Regorafenib—FRK—testis—ovarian cancer	0.00122	0.00877	CbGeAlD
Regorafenib—RET—embryo—ovarian cancer	0.00121	0.00864	CbGeAlD
Regorafenib—MAPK11—female gonad—ovarian cancer	0.00117	0.0084	CbGeAlD
Regorafenib—EPHA2—myometrium—ovarian cancer	0.00117	0.00839	CbGeAlD
Regorafenib—BRAF—endometrium—ovarian cancer	0.00116	0.00831	CbGeAlD
Regorafenib—FGFR2—embryo—ovarian cancer	0.00115	0.00821	CbGeAlD
Regorafenib—FLT4—epithelium—ovarian cancer	0.00112	0.00799	CbGeAlD
Regorafenib—FLT1—myometrium—ovarian cancer	0.00111	0.00791	CbGeAlD
Regorafenib—TEK—embryo—ovarian cancer	0.0011	0.00787	CbGeAlD
Regorafenib—RAF1—myometrium—ovarian cancer	0.0011	0.00787	CbGeAlD
Regorafenib—DDR2—testis—ovarian cancer	0.0011	0.00786	CbGeAlD
Regorafenib—FGFR1—uterine cervix—ovarian cancer	0.00109	0.00781	CbGeAlD
Regorafenib—BRAF—uterus—ovarian cancer	0.00107	0.00766	CbGeAlD
Regorafenib—FLT1—embryo—ovarian cancer	0.00106	0.00761	CbGeAlD
Regorafenib—RAF1—embryo—ovarian cancer	0.00106	0.00757	CbGeAlD
Regorafenib—FLT4—decidua—ovarian cancer	0.00105	0.00755	CbGeAlD
Regorafenib—MAPK11—testis—ovarian cancer	0.00104	0.00745	CbGeAlD
Regorafenib—FGFR1—decidua—ovarian cancer	0.00104	0.00745	CbGeAlD
Regorafenib—EPHX2—uterus—ovarian cancer	0.00102	0.00732	CbGeAlD
Regorafenib—PDGFRA—embryo—ovarian cancer	0.000996	0.00713	CbGeAlD
Regorafenib—RET—epithelium—ovarian cancer	0.000985	0.00705	CbGeAlD
Regorafenib—FGFR2—epithelium—ovarian cancer	0.000936	0.0067	CbGeAlD
Regorafenib—KDR—myometrium—ovarian cancer	0.000934	0.00669	CbGeAlD
Regorafenib—RET—decidua—ovarian cancer	0.000931	0.00666	CbGeAlD
Regorafenib—FGFR2—uterine cervix—ovarian cancer	0.000928	0.00664	CbGeAlD
Regorafenib—EPHA2—epithelium—ovarian cancer	0.00092	0.00659	CbGeAlD
Regorafenib—EPHA2—uterine cervix—ovarian cancer	0.000912	0.00653	CbGeAlD
Regorafenib—FGFR1—uterus—ovarian cancer	0.00091	0.00651	CbGeAlD
Regorafenib—BRAF—bone marrow—ovarian cancer	0.000908	0.0065	CbGeAlD
Regorafenib—KDR—embryo—ovarian cancer	0.000899	0.00644	CbGeAlD
Regorafenib—TEK—epithelium—ovarian cancer	0.000897	0.00643	CbGeAlD
Regorafenib—BRAF—female gonad—ovarian cancer	0.000875	0.00627	CbGeAlD
Regorafenib—BRAF—vagina—ovarian cancer	0.00087	0.00623	CbGeAlD
Regorafenib—EPHA2—decidua—ovarian cancer	0.000869	0.00622	CbGeAlD
Regorafenib—FLT1—epithelium—ovarian cancer	0.000868	0.00621	CbGeAlD
Regorafenib—RAF1—epithelium—ovarian cancer	0.000863	0.00618	CbGeAlD
Regorafenib—FLT1—uterine cervix—ovarian cancer	0.00086	0.00616	CbGeAlD
Regorafenib—RAF1—uterine cervix—ovarian cancer	0.000855	0.00612	CbGeAlD
Regorafenib—TEK—decidua—ovarian cancer	0.000848	0.00607	CbGeAlD
Regorafenib—EPHX2—female gonad—ovarian cancer	0.000836	0.00599	CbGeAlD
Regorafenib—EPHX2—vagina—ovarian cancer	0.000831	0.00595	CbGeAlD
Regorafenib—FLT4—female reproductive system—ovarian cancer	0.000829	0.00593	CbGeAlD
Regorafenib—KIT—myometrium—ovarian cancer	0.000828	0.00593	CbGeAlD
Regorafenib—EPHA2—endometrium—ovarian cancer	0.000825	0.00591	CbGeAlD
Regorafenib—FLT1—decidua—ovarian cancer	0.00082	0.00587	CbGeAlD
Regorafenib—RAF1—decidua—ovarian cancer	0.000815	0.00583	CbGeAlD
Regorafenib—PDGFRB—myometrium—ovarian cancer	0.000809	0.00579	CbGeAlD
Regorafenib—TEK—endometrium—ovarian cancer	0.000805	0.00576	CbGeAlD
Regorafenib—KIT—embryo—ovarian cancer	0.000796	0.0057	CbGeAlD
Regorafenib—DDR2—lymph node—ovarian cancer	0.000796	0.0057	CbGeAlD
Regorafenib—FLT4—bone marrow—ovarian cancer	0.000783	0.0056	CbGeAlD
Regorafenib—FLT1—endometrium—ovarian cancer	0.000778	0.00557	CbGeAlD
Regorafenib—PDGFRB—embryo—ovarian cancer	0.000778	0.00557	CbGeAlD
Regorafenib—BRAF—testis—ovarian cancer	0.000776	0.00556	CbGeAlD
Regorafenib—RAF1—endometrium—ovarian cancer	0.000773	0.00554	CbGeAlD
Regorafenib—FGFR2—uterus—ovarian cancer	0.000773	0.00554	CbGeAlD
Regorafenib—PDGFRA—decidua—ovarian cancer	0.000768	0.0055	CbGeAlD
Regorafenib—MAPK11—lymph node—ovarian cancer	0.000755	0.0054	CbGeAlD
Regorafenib—FLT4—female gonad—ovarian cancer	0.000754	0.0054	CbGeAlD
Regorafenib—FGFR1—female gonad—ovarian cancer	0.000744	0.00533	CbGeAlD
Regorafenib—EPHX2—testis—ovarian cancer	0.000742	0.00531	CbGeAlD
Regorafenib—TEK—uterus—ovarian cancer	0.000742	0.00531	CbGeAlD
Regorafenib—FGFR1—vagina—ovarian cancer	0.00074	0.0053	CbGeAlD
Regorafenib—KDR—epithelium—ovarian cancer	0.000733	0.00525	CbGeAlD
Regorafenib—KDR—uterine cervix—ovarian cancer	0.000727	0.00521	CbGeAlD
Regorafenib—FLT1—gonad—ovarian cancer	0.000722	0.00517	CbGeAlD
Regorafenib—ABL1—myometrium—ovarian cancer	0.000721	0.00516	CbGeAlD
Regorafenib—RAF1—gonad—ovarian cancer	0.000717	0.00514	CbGeAlD
Regorafenib—FLT1—uterus—ovarian cancer	0.000717	0.00513	CbGeAlD
Regorafenib—RAF1—uterus—ovarian cancer	0.000713	0.0051	CbGeAlD
Regorafenib—FGFR2—female reproductive system—ovarian cancer	0.000695	0.00498	CbGeAlD
Regorafenib—ABL1—embryo—ovarian cancer	0.000693	0.00496	CbGeAlD
Regorafenib—KDR—decidua—ovarian cancer	0.000693	0.00496	CbGeAlD
Regorafenib—EPHA2—female reproductive system—ovarian cancer	0.000683	0.00489	CbGeAlD
Regorafenib—PDGFRA—gonad—ovarian cancer	0.000676	0.00484	CbGeAlD
Regorafenib—PDGFRA—uterus—ovarian cancer	0.000672	0.00481	CbGeAlD
Regorafenib—FLT4—testis—ovarian cancer	0.000669	0.00479	CbGeAlD
Regorafenib—TEK—female reproductive system—ovarian cancer	0.000667	0.00477	CbGeAlD
Regorafenib—FGFR1—testis—ovarian cancer	0.00066	0.00473	CbGeAlD
Regorafenib—KDR—endometrium—ovarian cancer	0.000658	0.00471	CbGeAlD
Regorafenib—KIT—epithelium—ovarian cancer	0.00065	0.00465	CbGeAlD
Regorafenib—FLT1—female reproductive system—ovarian cancer	0.000644	0.00461	CbGeAlD
Regorafenib—KIT—uterine cervix—ovarian cancer	0.000644	0.00461	CbGeAlD
Regorafenib—RAF1—female reproductive system—ovarian cancer	0.000641	0.00459	CbGeAlD
Regorafenib—PDGFRB—epithelium—ovarian cancer	0.000635	0.00455	CbGeAlD
Regorafenib—FGFR2—female gonad—ovarian cancer	0.000633	0.00453	CbGeAlD
Regorafenib—PDGFRB—uterine cervix—ovarian cancer	0.000629	0.00451	CbGeAlD
Regorafenib—EPHA2—female gonad—ovarian cancer	0.000622	0.00445	CbGeAlD
Regorafenib—EPHA2—vagina—ovarian cancer	0.000618	0.00442	CbGeAlD
Regorafenib—KIT—decidua—ovarian cancer	0.000614	0.0044	CbGeAlD
Regorafenib—ABL1—Doxorubicin—Epirubicin—ovarian cancer	0.000609	0.173	CbGdCrCtD
Regorafenib—ABL1—Idarubicin—Epirubicin—ovarian cancer	0.000609	0.173	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Epirubicin—ovarian cancer	0.000609	0.173	CbGdCrCtD
Regorafenib—TEK—female gonad—ovarian cancer	0.000607	0.00434	CbGeAlD
Regorafenib—KDR—uterus—ovarian cancer	0.000606	0.00434	CbGeAlD
Regorafenib—RAF1—bone marrow—ovarian cancer	0.000605	0.00433	CbGeAlD
Regorafenib—PDGFRA—female reproductive system—ovarian cancer	0.000604	0.00432	CbGeAlD
Regorafenib—PDGFRB—decidua—ovarian cancer	0.0006	0.00429	CbGeAlD
Regorafenib—RET—testis—ovarian cancer	0.000591	0.00423	CbGeAlD
Regorafenib—FLT1—female gonad—ovarian cancer	0.000586	0.0042	CbGeAlD
Regorafenib—RAF1—female gonad—ovarian cancer	0.000583	0.00417	CbGeAlD
Regorafenib—FLT1—vagina—ovarian cancer	0.000583	0.00417	CbGeAlD
Regorafenib—KIT—endometrium—ovarian cancer	0.000583	0.00417	CbGeAlD
Regorafenib—RAF1—vagina—ovarian cancer	0.000579	0.00415	CbGeAlD
Regorafenib—PDGFRB—endometrium—ovarian cancer	0.000569	0.00408	CbGeAlD
Regorafenib—ABL1—Idarubicin—Doxorubicin—ovarian cancer	0.000563	0.16	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Doxorubicin—ovarian cancer	0.000563	0.16	CbGdCrCtD
Regorafenib—ABL1—Epirubicin—Doxorubicin—ovarian cancer	0.000563	0.16	CbGdCrCtD
Regorafenib—BRAF—lymph node—ovarian cancer	0.000563	0.00403	CbGeAlD
Regorafenib—FGFR2—testis—ovarian cancer	0.000561	0.00402	CbGeAlD
Regorafenib—ABL1—uterine cervix—ovarian cancer	0.000561	0.00402	CbGeAlD
Regorafenib—EPHA2—testis—ovarian cancer	0.000551	0.00395	CbGeAlD
Regorafenib—PDGFRA—female gonad—ovarian cancer	0.00055	0.00393	CbGeAlD
Regorafenib—PDGFRA—vagina—ovarian cancer	0.000546	0.00391	CbGeAlD
Regorafenib—KDR—female reproductive system—ovarian cancer	0.000545	0.0039	CbGeAlD
Regorafenib—KIT—gonad—ovarian cancer	0.000541	0.00387	CbGeAlD
Regorafenib—TEK—testis—ovarian cancer	0.000538	0.00385	CbGeAlD
Regorafenib—EPHX2—lymph node—ovarian cancer	0.000538	0.00385	CbGeAlD
Regorafenib—KIT—uterus—ovarian cancer	0.000537	0.00385	CbGeAlD
Regorafenib—ABL1—decidua—ovarian cancer	0.000534	0.00383	CbGeAlD
Regorafenib—PDGFRB—gonad—ovarian cancer	0.000528	0.00378	CbGeAlD
Regorafenib—PDGFRB—uterus—ovarian cancer	0.000525	0.00376	CbGeAlD
Regorafenib—FLT1—testis—ovarian cancer	0.00052	0.00372	CbGeAlD
Regorafenib—RAF1—testis—ovarian cancer	0.000517	0.0037	CbGeAlD
Regorafenib—KDR—bone marrow—ovarian cancer	0.000514	0.00368	CbGeAlD
Regorafenib—ABL1—endometrium—ovarian cancer	0.000507	0.00363	CbGeAlD
Regorafenib—KDR—female gonad—ovarian cancer	0.000496	0.00355	CbGeAlD
Regorafenib—KDR—vagina—ovarian cancer	0.000493	0.00353	CbGeAlD
Regorafenib—PDGFRA—testis—ovarian cancer	0.000487	0.00349	CbGeAlD
Regorafenib—FLT4—lymph node—ovarian cancer	0.000485	0.00347	CbGeAlD
Regorafenib—KIT—female reproductive system—ovarian cancer	0.000483	0.00346	CbGeAlD
Regorafenib—FGFR1—lymph node—ovarian cancer	0.000478	0.00343	CbGeAlD
Regorafenib—PDGFRB—female reproductive system—ovarian cancer	0.000472	0.00338	CbGeAlD
Regorafenib—ABL1—gonad—ovarian cancer	0.000471	0.00337	CbGeAlD
Regorafenib—ABL1—uterus—ovarian cancer	0.000468	0.00335	CbGeAlD
Regorafenib—KIT—bone marrow—ovarian cancer	0.000456	0.00326	CbGeAlD
Regorafenib—ABCG2—myometrium—ovarian cancer	0.000455	0.00325	CbGeAlD
Regorafenib—PDGFRB—bone marrow—ovarian cancer	0.000445	0.00319	CbGeAlD
Regorafenib—KDR—testis—ovarian cancer	0.00044	0.00315	CbGeAlD
Regorafenib—KIT—female gonad—ovarian cancer	0.000439	0.00315	CbGeAlD
Regorafenib—KIT—vagina—ovarian cancer	0.000437	0.00313	CbGeAlD
Regorafenib—PDGFRB—female gonad—ovarian cancer	0.000429	0.00307	CbGeAlD
Regorafenib—RET—lymph node—ovarian cancer	0.000428	0.00307	CbGeAlD
Regorafenib—PDGFRB—vagina—ovarian cancer	0.000426	0.00305	CbGeAlD
Regorafenib—ABL1—female reproductive system—ovarian cancer	0.00042	0.00301	CbGeAlD
Regorafenib—EPHA2—lymph node—ovarian cancer	0.0004	0.00286	CbGeAlD
Regorafenib—ABL1—bone marrow—ovarian cancer	0.000397	0.00284	CbGeAlD
Regorafenib—TEK—lymph node—ovarian cancer	0.00039	0.00279	CbGeAlD
Regorafenib—KIT—testis—ovarian cancer	0.00039	0.00279	CbGeAlD
Regorafenib—ABL1—female gonad—ovarian cancer	0.000382	0.00274	CbGeAlD
Regorafenib—PDGFRB—testis—ovarian cancer	0.000381	0.00272	CbGeAlD
Regorafenib—ABL1—vagina—ovarian cancer	0.00038	0.00272	CbGeAlD
Regorafenib—FLT1—lymph node—ovarian cancer	0.000377	0.0027	CbGeAlD
Regorafenib—RAF1—lymph node—ovarian cancer	0.000375	0.00268	CbGeAlD
Regorafenib—ABCG2—uterine cervix—ovarian cancer	0.000354	0.00253	CbGeAlD
Regorafenib—PDGFRA—lymph node—ovarian cancer	0.000353	0.00253	CbGeAlD
Regorafenib—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.000349	0.00232	CcSEcCtD
Regorafenib—Anaemia—Vinorelbine—ovarian cancer	0.000348	0.00232	CcSEcCtD
Regorafenib—Fatigue—Chlorambucil—ovarian cancer	0.000348	0.00232	CcSEcCtD
Regorafenib—Pain—Chlorambucil—ovarian cancer	0.000345	0.0023	CcSEcCtD
Regorafenib—Thrombocytopenia—Melphalan—ovarian cancer	0.000345	0.0023	CcSEcCtD
Regorafenib—Skin disorder—Melphalan—ovarian cancer	0.000342	0.00228	CcSEcCtD
Regorafenib—Neutropenia—Paclitaxel—ovarian cancer	0.00034	0.00227	CcSEcCtD
Regorafenib—ABL1—testis—ovarian cancer	0.000339	0.00243	CbGeAlD
Regorafenib—Blood uric acid increased—Epirubicin—ovarian cancer	0.000338	0.00225	CcSEcCtD
Regorafenib—Leukopenia—Vinorelbine—ovarian cancer	0.000337	0.00225	CcSEcCtD
Regorafenib—Hyperbilirubinaemia—Doxorubicin—ovarian cancer	0.000337	0.00225	CcSEcCtD
Regorafenib—ABCG2—decidua—ovarian cancer	0.000337	0.00241	CbGeAlD
Regorafenib—Hypocalcaemia—Doxorubicin—ovarian cancer	0.000335	0.00223	CcSEcCtD
Regorafenib—Hyperuricaemia—Doxorubicin—ovarian cancer	0.000331	0.0022	CcSEcCtD
Regorafenib—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.00033	0.0022	CcSEcCtD
Regorafenib—Weight decreased—Paclitaxel—ovarian cancer	0.000329	0.00219	CcSEcCtD
Regorafenib—CYP2C8—endometrium—ovarian cancer	0.000329	0.00236	CbGeAlD
Regorafenib—Dry skin—Docetaxel—ovarian cancer	0.000327	0.00218	CcSEcCtD
Regorafenib—Hypertension—Vinorelbine—ovarian cancer	0.000325	0.00217	CcSEcCtD
Regorafenib—Infestation—Paclitaxel—ovarian cancer	0.000324	0.00216	CcSEcCtD
Regorafenib—Infestation NOS—Paclitaxel—ovarian cancer	0.000324	0.00216	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Paclitaxel—ovarian cancer	0.000322	0.00214	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Docetaxel—ovarian cancer	0.000321	0.00214	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Docetaxel—ovarian cancer	0.000321	0.00214	CcSEcCtD
Regorafenib—ABCG2—endometrium—ovarian cancer	0.00032	0.00229	CbGeAlD
Regorafenib—Acute coronary syndrome—Paclitaxel—ovarian cancer	0.00032	0.00213	CcSEcCtD
Regorafenib—Abdominal pain—Chlorambucil—ovarian cancer	0.000319	0.00213	CcSEcCtD
Regorafenib—Body temperature increased—Chlorambucil—ovarian cancer	0.000319	0.00213	CcSEcCtD
Regorafenib—KDR—lymph node—ovarian cancer	0.000319	0.00228	CbGeAlD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000319	0.00212	CcSEcCtD
Regorafenib—Myocardial infarction—Paclitaxel—ovarian cancer	0.000318	0.00212	CcSEcCtD
Regorafenib—Stomatitis—Paclitaxel—ovarian cancer	0.000316	0.00211	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Docetaxel—ovarian cancer	0.000315	0.0021	CcSEcCtD
Regorafenib—Decreased appetite—Topotecan—ovarian cancer	0.000313	0.00208	CcSEcCtD
Regorafenib—Blood uric acid increased—Doxorubicin—ovarian cancer	0.000312	0.00208	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00031	0.00207	CcSEcCtD
Regorafenib—Fatigue—Topotecan—ovarian cancer	0.00031	0.00206	CcSEcCtD
Regorafenib—Pain—Topotecan—ovarian cancer	0.000307	0.00205	CcSEcCtD
Regorafenib—Hepatobiliary disease—Paclitaxel—ovarian cancer	0.000307	0.00204	CcSEcCtD
Regorafenib—Decreased appetite—Melphalan—ovarian cancer	0.000306	0.00204	CcSEcCtD
Regorafenib—Infection—Vinorelbine—ovarian cancer	0.000306	0.00203	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000304	0.00202	CcSEcCtD
Regorafenib—Fatigue—Melphalan—ovarian cancer	0.000304	0.00202	CcSEcCtD
Regorafenib—Nervous system disorder—Vinorelbine—ovarian cancer	0.000302	0.00201	CcSEcCtD
Regorafenib—Thrombocytopenia—Vinorelbine—ovarian cancer	0.000301	0.00201	CcSEcCtD
Regorafenib—Pain—Melphalan—ovarian cancer	0.000301	0.002	CcSEcCtD
Regorafenib—Neoplasm—Epirubicin—ovarian cancer	0.0003	0.002	CcSEcCtD
Regorafenib—Skin disorder—Vinorelbine—ovarian cancer	0.000299	0.00199	CcSEcCtD
Regorafenib—ABCG2—uterus—ovarian cancer	0.000295	0.00211	CbGeAlD
Regorafenib—Gastrointestinal pain—Topotecan—ovarian cancer	0.000294	0.00196	CcSEcCtD
Regorafenib—Haemoglobin—Paclitaxel—ovarian cancer	0.000293	0.00195	CcSEcCtD
Regorafenib—Haemorrhage—Paclitaxel—ovarian cancer	0.000291	0.00194	CcSEcCtD
Regorafenib—Asthenia—Chlorambucil—ovarian cancer	0.00029	0.00193	CcSEcCtD
Regorafenib—Neutropenia—Docetaxel—ovarian cancer	0.000288	0.00192	CcSEcCtD
Regorafenib—Urinary tract disorder—Paclitaxel—ovarian cancer	0.000288	0.00191	CcSEcCtD
Regorafenib—Connective tissue disorder—Paclitaxel—ovarian cancer	0.000286	0.00191	CcSEcCtD
Regorafenib—Urethral disorder—Paclitaxel—ovarian cancer	0.000285	0.0019	CcSEcCtD
Regorafenib—Abdominal pain—Topotecan—ovarian cancer	0.000284	0.00189	CcSEcCtD
Regorafenib—Body temperature increased—Topotecan—ovarian cancer	0.000284	0.00189	CcSEcCtD
Regorafenib—CYP2C19—vagina—ovarian cancer	0.000282	0.00202	CbGeAlD
Regorafenib—KIT—lymph node—ovarian cancer	0.000282	0.00202	CbGeAlD
Regorafenib—Weight decreased—Docetaxel—ovarian cancer	0.000279	0.00186	CcSEcCtD
Regorafenib—Neoplasm—Doxorubicin—ovarian cancer	0.000277	0.00185	CcSEcCtD
Regorafenib—Diarrhoea—Chlorambucil—ovarian cancer	0.000276	0.00184	CcSEcCtD
Regorafenib—PDGFRB—lymph node—ovarian cancer	0.000276	0.00198	CbGeAlD
Regorafenib—Erythema multiforme—Paclitaxel—ovarian cancer	0.000275	0.00183	CcSEcCtD
Regorafenib—Infestation NOS—Docetaxel—ovarian cancer	0.000275	0.00183	CcSEcCtD
Regorafenib—Infestation—Docetaxel—ovarian cancer	0.000275	0.00183	CcSEcCtD
Regorafenib—CYP2B6—gonad—ovarian cancer	0.000274	0.00196	CbGeAlD
Regorafenib—CYP2C8—female reproductive system—ovarian cancer	0.000273	0.00195	CbGeAlD
Regorafenib—Stevens-Johnson syndrome—Docetaxel—ovarian cancer	0.000273	0.00182	CcSEcCtD
Regorafenib—Acute coronary syndrome—Docetaxel—ovarian cancer	0.000271	0.0018	CcSEcCtD
Regorafenib—Cardiac disorder—Paclitaxel—ovarian cancer	0.00027	0.0018	CcSEcCtD
Regorafenib—Myocardial infarction—Docetaxel—ovarian cancer	0.000269	0.00179	CcSEcCtD
Regorafenib—Stomatitis—Docetaxel—ovarian cancer	0.000268	0.00178	CcSEcCtD
Regorafenib—Decreased appetite—Vinorelbine—ovarian cancer	0.000267	0.00178	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000266	0.00177	CcSEcCtD
Regorafenib—Fatigue—Vinorelbine—ovarian cancer	0.000265	0.00177	CcSEcCtD
Regorafenib—Angiopathy—Paclitaxel—ovarian cancer	0.000264	0.00176	CcSEcCtD
Regorafenib—Pain—Vinorelbine—ovarian cancer	0.000263	0.00175	CcSEcCtD
Regorafenib—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000262	0.00175	CcSEcCtD
Regorafenib—Hepatobiliary disease—Docetaxel—ovarian cancer	0.00026	0.00173	CcSEcCtD
Regorafenib—Asthenia—Topotecan—ovarian cancer	0.000258	0.00172	CcSEcCtD
Regorafenib—Alopecia—Paclitaxel—ovarian cancer	0.000257	0.00171	CcSEcCtD
Regorafenib—Vomiting—Chlorambucil—ovarian cancer	0.000257	0.00171	CcSEcCtD
Regorafenib—Malnutrition—Paclitaxel—ovarian cancer	0.000253	0.00169	CcSEcCtD
Regorafenib—Asthenia—Melphalan—ovarian cancer	0.000253	0.00168	CcSEcCtD
Regorafenib—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000251	0.00167	CcSEcCtD
Regorafenib—ABCG2—bone marrow—ovarian cancer	0.00025	0.00179	CbGeAlD
Regorafenib—Haemoglobin—Docetaxel—ovarian cancer	0.000248	0.00165	CcSEcCtD
Regorafenib—Haemorrhage—Docetaxel—ovarian cancer	0.000247	0.00164	CcSEcCtD
Regorafenib—CYP2C8—vagina—ovarian cancer	0.000247	0.00177	CbGeAlD
Regorafenib—Diarrhoea—Topotecan—ovarian cancer	0.000246	0.00164	CcSEcCtD
Regorafenib—ABL1—lymph node—ovarian cancer	0.000246	0.00176	CbGeAlD
Regorafenib—CYP2B6—female reproductive system—ovarian cancer	0.000245	0.00175	CbGeAlD
Regorafenib—Urinary tract disorder—Docetaxel—ovarian cancer	0.000244	0.00162	CcSEcCtD
Regorafenib—Abdominal pain—Vinorelbine—ovarian cancer	0.000243	0.00162	CcSEcCtD
Regorafenib—Body temperature increased—Vinorelbine—ovarian cancer	0.000243	0.00162	CcSEcCtD
Regorafenib—Connective tissue disorder—Docetaxel—ovarian cancer	0.000243	0.00161	CcSEcCtD
Regorafenib—CYP2C9—female reproductive system—ovarian cancer	0.000242	0.00173	CbGeAlD
Regorafenib—Urethral disorder—Docetaxel—ovarian cancer	0.000242	0.00161	CcSEcCtD
Regorafenib—Hyponatraemia—Epirubicin—ovarian cancer	0.000242	0.00161	CcSEcCtD
Regorafenib—ABCG2—female gonad—ovarian cancer	0.000241	0.00173	CbGeAlD
Regorafenib—Diarrhoea—Melphalan—ovarian cancer	0.000241	0.0016	CcSEcCtD
Regorafenib—Nausea—Chlorambucil—ovarian cancer	0.00024	0.0016	CcSEcCtD
Regorafenib—ABCG2—vagina—ovarian cancer	0.00024	0.00172	CbGeAlD
Regorafenib—Tremor—Paclitaxel—ovarian cancer	0.000237	0.00158	CcSEcCtD
Regorafenib—Anaemia—Paclitaxel—ovarian cancer	0.000234	0.00156	CcSEcCtD
Regorafenib—Erythema multiforme—Docetaxel—ovarian cancer	0.000233	0.00155	CcSEcCtD
Regorafenib—Cardiac disorder—Docetaxel—ovarian cancer	0.000229	0.00153	CcSEcCtD
Regorafenib—Vomiting—Topotecan—ovarian cancer	0.000229	0.00152	CcSEcCtD
Regorafenib—Leukopenia—Paclitaxel—ovarian cancer	0.000227	0.00151	CcSEcCtD
Regorafenib—Rash—Topotecan—ovarian cancer	0.000227	0.00151	CcSEcCtD
Regorafenib—Dermatitis—Topotecan—ovarian cancer	0.000226	0.00151	CcSEcCtD
Regorafenib—Headache—Topotecan—ovarian cancer	0.000225	0.0015	CcSEcCtD
Regorafenib—ABCB1—myometrium—ovarian cancer	0.000224	0.0016	CbGeAlD
Regorafenib—Angiopathy—Docetaxel—ovarian cancer	0.000224	0.00149	CcSEcCtD
Regorafenib—Vomiting—Melphalan—ovarian cancer	0.000224	0.00149	CcSEcCtD
Regorafenib—Hyponatraemia—Doxorubicin—ovarian cancer	0.000224	0.00149	CcSEcCtD
Regorafenib—Mediastinal disorder—Docetaxel—ovarian cancer	0.000222	0.00148	CcSEcCtD
Regorafenib—Rash—Melphalan—ovarian cancer	0.000222	0.00148	CcSEcCtD
Regorafenib—Dermatitis—Melphalan—ovarian cancer	0.000222	0.00148	CcSEcCtD
Regorafenib—CYP2B6—vagina—ovarian cancer	0.000221	0.00158	CbGeAlD
Regorafenib—Asthenia—Vinorelbine—ovarian cancer	0.000221	0.00147	CcSEcCtD
Regorafenib—Dry skin—Epirubicin—ovarian cancer	0.000221	0.00147	CcSEcCtD
Regorafenib—CYP2C8—testis—ovarian cancer	0.00022	0.00158	CbGeAlD
Regorafenib—Hypokalaemia—Epirubicin—ovarian cancer	0.000219	0.00146	CcSEcCtD
Regorafenib—Hypertension—Paclitaxel—ovarian cancer	0.000219	0.00146	CcSEcCtD
Regorafenib—Alopecia—Docetaxel—ovarian cancer	0.000218	0.00145	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.000217	0.00144	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000217	0.00144	CcSEcCtD
Regorafenib—ABCB1—embryo—ovarian cancer	0.000216	0.00154	CbGeAlD
Regorafenib—Malnutrition—Docetaxel—ovarian cancer	0.000215	0.00143	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000214	0.00143	CcSEcCtD
Regorafenib—ABCG2—testis—ovarian cancer	0.000214	0.00153	CbGeAlD
Regorafenib—Nausea—Topotecan—ovarian cancer	0.000214	0.00142	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000212	0.00141	CcSEcCtD
Regorafenib—Dry mouth—Paclitaxel—ovarian cancer	0.000211	0.00141	CcSEcCtD
Regorafenib—Diarrhoea—Vinorelbine—ovarian cancer	0.00021	0.0014	CcSEcCtD
Regorafenib—Nausea—Melphalan—ovarian cancer	0.000209	0.00139	CcSEcCtD
Regorafenib—Infection—Paclitaxel—ovarian cancer	0.000206	0.00137	CcSEcCtD
Regorafenib—Dry skin—Doxorubicin—ovarian cancer	0.000204	0.00136	CcSEcCtD
Regorafenib—Nervous system disorder—Paclitaxel—ovarian cancer	0.000203	0.00135	CcSEcCtD
Regorafenib—Hypokalaemia—Doxorubicin—ovarian cancer	0.000203	0.00135	CcSEcCtD
Regorafenib—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000203	0.00135	CcSEcCtD
Regorafenib—Skin disorder—Paclitaxel—ovarian cancer	0.000201	0.00134	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.0002	0.00134	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.0002	0.00134	CcSEcCtD
Regorafenib—Anaemia—Docetaxel—ovarian cancer	0.000199	0.00132	CcSEcCtD
Regorafenib—CYP2B6—testis—ovarian cancer	0.000197	0.00141	CbGeAlD
Regorafenib—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000196	0.00131	CcSEcCtD
Regorafenib—Vomiting—Vinorelbine—ovarian cancer	0.000196	0.0013	CcSEcCtD
Regorafenib—Neutropenia—Epirubicin—ovarian cancer	0.000194	0.0013	CcSEcCtD
Regorafenib—Rash—Vinorelbine—ovarian cancer	0.000194	0.00129	CcSEcCtD
Regorafenib—Dermatitis—Vinorelbine—ovarian cancer	0.000194	0.00129	CcSEcCtD
Regorafenib—Headache—Vinorelbine—ovarian cancer	0.000193	0.00128	CcSEcCtD
Regorafenib—Leukopenia—Docetaxel—ovarian cancer	0.000192	0.00128	CcSEcCtD
Regorafenib—Weight decreased—Epirubicin—ovarian cancer	0.000188	0.00125	CcSEcCtD
Regorafenib—Hypertension—Docetaxel—ovarian cancer	0.000185	0.00124	CcSEcCtD
Regorafenib—Infestation NOS—Epirubicin—ovarian cancer	0.000185	0.00123	CcSEcCtD
Regorafenib—Infestation—Epirubicin—ovarian cancer	0.000185	0.00123	CcSEcCtD
Regorafenib—CYP3A4—female reproductive system—ovarian cancer	0.000185	0.00132	CbGeAlD
Regorafenib—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000184	0.00122	CcSEcCtD
Regorafenib—Nausea—Vinorelbine—ovarian cancer	0.000183	0.00122	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000182	0.00121	CcSEcCtD
Regorafenib—Stomatitis—Epirubicin—ovarian cancer	0.000181	0.0012	CcSEcCtD
Regorafenib—Neutropenia—Doxorubicin—ovarian cancer	0.00018	0.0012	CcSEcCtD
Regorafenib—Decreased appetite—Paclitaxel—ovarian cancer	0.00018	0.0012	CcSEcCtD
Regorafenib—Dry mouth—Docetaxel—ovarian cancer	0.000179	0.00119	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000179	0.00119	CcSEcCtD
Regorafenib—Fatigue—Paclitaxel—ovarian cancer	0.000178	0.00119	CcSEcCtD
Regorafenib—Pain—Paclitaxel—ovarian cancer	0.000177	0.00118	CcSEcCtD
Regorafenib—ABCB1—epithelium—ovarian cancer	0.000176	0.00126	CbGeAlD
Regorafenib—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000175	0.00117	CcSEcCtD
Regorafenib—ABCB1—uterine cervix—ovarian cancer	0.000174	0.00125	CbGeAlD
Regorafenib—Infection—Docetaxel—ovarian cancer	0.000174	0.00116	CcSEcCtD
Regorafenib—Weight decreased—Doxorubicin—ovarian cancer	0.000174	0.00116	CcSEcCtD
Regorafenib—Nervous system disorder—Docetaxel—ovarian cancer	0.000172	0.00115	CcSEcCtD
Regorafenib—Thrombocytopenia—Docetaxel—ovarian cancer	0.000172	0.00114	CcSEcCtD
Regorafenib—Infestation NOS—Doxorubicin—ovarian cancer	0.000172	0.00114	CcSEcCtD
Regorafenib—Infestation—Doxorubicin—ovarian cancer	0.000172	0.00114	CcSEcCtD
Regorafenib—Skin disorder—Docetaxel—ovarian cancer	0.00017	0.00113	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.00017	0.00113	CcSEcCtD
Regorafenib—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000169	0.00113	CcSEcCtD
Regorafenib—Haemoglobin—Epirubicin—ovarian cancer	0.000167	0.00111	CcSEcCtD
Regorafenib—Stomatitis—Doxorubicin—ovarian cancer	0.000167	0.00111	CcSEcCtD
Regorafenib—Haemorrhage—Epirubicin—ovarian cancer	0.000166	0.00111	CcSEcCtD
Regorafenib—ABCB1—decidua—ovarian cancer	0.000166	0.00119	CbGeAlD
Regorafenib—Urinary tract disorder—Epirubicin—ovarian cancer	0.000164	0.00109	CcSEcCtD
Regorafenib—Connective tissue disorder—Epirubicin—ovarian cancer	0.000164	0.00109	CcSEcCtD
Regorafenib—Body temperature increased—Paclitaxel—ovarian cancer	0.000164	0.00109	CcSEcCtD
Regorafenib—Abdominal pain—Paclitaxel—ovarian cancer	0.000164	0.00109	CcSEcCtD
Regorafenib—Urethral disorder—Epirubicin—ovarian cancer	0.000163	0.00109	CcSEcCtD
Regorafenib—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000162	0.00108	CcSEcCtD
Regorafenib—ABCB1—endometrium—ovarian cancer	0.000158	0.00113	CbGeAlD
Regorafenib—Erythema multiforme—Epirubicin—ovarian cancer	0.000157	0.00105	CcSEcCtD
Regorafenib—ABCG2—lymph node—ovarian cancer	0.000155	0.00111	CbGeAlD
Regorafenib—Haemoglobin—Doxorubicin—ovarian cancer	0.000155	0.00103	CcSEcCtD
Regorafenib—Cardiac disorder—Epirubicin—ovarian cancer	0.000154	0.00103	CcSEcCtD
Regorafenib—Haemorrhage—Doxorubicin—ovarian cancer	0.000154	0.00103	CcSEcCtD
Regorafenib—Decreased appetite—Docetaxel—ovarian cancer	0.000152	0.00101	CcSEcCtD
Regorafenib—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000152	0.00101	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000151	0.00101	CcSEcCtD
Regorafenib—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000151	0.00101	CcSEcCtD
Regorafenib—Fatigue—Docetaxel—ovarian cancer	0.000151	0.00101	CcSEcCtD
Regorafenib—Angiopathy—Epirubicin—ovarian cancer	0.000151	0.00101	CcSEcCtD
Regorafenib—Urethral disorder—Doxorubicin—ovarian cancer	0.000151	0.00101	CcSEcCtD
Regorafenib—Mediastinal disorder—Epirubicin—ovarian cancer	0.00015	0.000999	CcSEcCtD
Regorafenib—Pain—Docetaxel—ovarian cancer	0.00015	0.000998	CcSEcCtD
Regorafenib—Asthenia—Paclitaxel—ovarian cancer	0.000148	0.000988	CcSEcCtD
Regorafenib—Alopecia—Epirubicin—ovarian cancer	0.000147	0.00098	CcSEcCtD
Regorafenib—ABCB1—gonad—ovarian cancer	0.000146	0.00105	CbGeAlD
Regorafenib—Erythema multiforme—Doxorubicin—ovarian cancer	0.000146	0.00097	CcSEcCtD
Regorafenib—ABCB1—uterus—ovarian cancer	0.000145	0.00104	CbGeAlD
Regorafenib—Malnutrition—Epirubicin—ovarian cancer	0.000145	0.000965	CcSEcCtD
Regorafenib—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000143	0.000955	CcSEcCtD
Regorafenib—Cardiac disorder—Doxorubicin—ovarian cancer	0.000143	0.000952	CcSEcCtD
Regorafenib—Diarrhoea—Paclitaxel—ovarian cancer	0.000142	0.000943	CcSEcCtD
Regorafenib—Angiopathy—Doxorubicin—ovarian cancer	0.00014	0.000931	CcSEcCtD
Regorafenib—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000139	0.000924	CcSEcCtD
Regorafenib—Body temperature increased—Docetaxel—ovarian cancer	0.000139	0.000923	CcSEcCtD
Regorafenib—Abdominal pain—Docetaxel—ovarian cancer	0.000139	0.000923	CcSEcCtD
Regorafenib—Alopecia—Doxorubicin—ovarian cancer	0.000136	0.000906	CcSEcCtD
Regorafenib—Malnutrition—Doxorubicin—ovarian cancer	0.000134	0.000893	CcSEcCtD
Regorafenib—Anaemia—Epirubicin—ovarian cancer	0.000134	0.000892	CcSEcCtD
Regorafenib—Vomiting—Paclitaxel—ovarian cancer	0.000132	0.000876	CcSEcCtD
Regorafenib—ABCB1—female reproductive system—ovarian cancer	0.000131	0.000936	CbGeAlD
Regorafenib—Rash—Paclitaxel—ovarian cancer	0.00013	0.000869	CcSEcCtD
Regorafenib—Dermatitis—Paclitaxel—ovarian cancer	0.00013	0.000868	CcSEcCtD
Regorafenib—Leukopenia—Epirubicin—ovarian cancer	0.00013	0.000864	CcSEcCtD
Regorafenib—Headache—Paclitaxel—ovarian cancer	0.00013	0.000863	CcSEcCtD
Regorafenib—Asthenia—Docetaxel—ovarian cancer	0.000126	0.000838	CcSEcCtD
Regorafenib—Hypertension—Epirubicin—ovarian cancer	0.000125	0.000833	CcSEcCtD
Regorafenib—Anaemia—Doxorubicin—ovarian cancer	0.000124	0.000825	CcSEcCtD
Regorafenib—ABCB1—bone marrow—ovarian cancer	0.000123	0.000883	CbGeAlD
Regorafenib—Nausea—Paclitaxel—ovarian cancer	0.000123	0.000818	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000123	0.000816	CcSEcCtD
Regorafenib—Dry mouth—Epirubicin—ovarian cancer	0.000121	0.000803	CcSEcCtD
Regorafenib—Leukopenia—Doxorubicin—ovarian cancer	0.00012	0.000799	CcSEcCtD
Regorafenib—Diarrhoea—Docetaxel—ovarian cancer	0.00012	0.000799	CcSEcCtD
Regorafenib—ABCB1—female gonad—ovarian cancer	0.000119	0.000852	CbGeAlD
Regorafenib—ABCB1—vagina—ovarian cancer	0.000118	0.000846	CbGeAlD
Regorafenib—Infection—Epirubicin—ovarian cancer	0.000117	0.000782	CcSEcCtD
Regorafenib—Nervous system disorder—Epirubicin—ovarian cancer	0.000116	0.000772	CcSEcCtD
Regorafenib—Thrombocytopenia—Epirubicin—ovarian cancer	0.000116	0.000771	CcSEcCtD
Regorafenib—Hypertension—Doxorubicin—ovarian cancer	0.000116	0.000771	CcSEcCtD
Regorafenib—Skin disorder—Epirubicin—ovarian cancer	0.000115	0.000765	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000113	0.000755	CcSEcCtD
Regorafenib—Dry mouth—Doxorubicin—ovarian cancer	0.000112	0.000743	CcSEcCtD
Regorafenib—Vomiting—Docetaxel—ovarian cancer	0.000111	0.000742	CcSEcCtD
Regorafenib—Rash—Docetaxel—ovarian cancer	0.000111	0.000736	CcSEcCtD
Regorafenib—Dermatitis—Docetaxel—ovarian cancer	0.00011	0.000736	CcSEcCtD
Regorafenib—Headache—Docetaxel—ovarian cancer	0.00011	0.000731	CcSEcCtD
Regorafenib—Infection—Doxorubicin—ovarian cancer	0.000109	0.000724	CcSEcCtD
Regorafenib—Nervous system disorder—Doxorubicin—ovarian cancer	0.000107	0.000715	CcSEcCtD
Regorafenib—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000107	0.000713	CcSEcCtD
Regorafenib—Skin disorder—Doxorubicin—ovarian cancer	0.000106	0.000708	CcSEcCtD
Regorafenib—ABCB1—testis—ovarian cancer	0.000105	0.000755	CbGeAlD
Regorafenib—Nausea—Docetaxel—ovarian cancer	0.000104	0.000694	CcSEcCtD
Regorafenib—Decreased appetite—Epirubicin—ovarian cancer	0.000103	0.000685	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000102	0.00068	CcSEcCtD
Regorafenib—Fatigue—Epirubicin—ovarian cancer	0.000102	0.000679	CcSEcCtD
Regorafenib—Pain—Epirubicin—ovarian cancer	0.000101	0.000673	CcSEcCtD
Regorafenib—Gastrointestinal pain—Epirubicin—ovarian cancer	9.67e-05	0.000644	CcSEcCtD
Regorafenib—Decreased appetite—Doxorubicin—ovarian cancer	9.51e-05	0.000633	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	9.45e-05	0.000629	CcSEcCtD
Regorafenib—Fatigue—Doxorubicin—ovarian cancer	9.43e-05	0.000628	CcSEcCtD
Regorafenib—Pain—Doxorubicin—ovarian cancer	9.36e-05	0.000623	CcSEcCtD
Regorafenib—Body temperature increased—Epirubicin—ovarian cancer	9.35e-05	0.000623	CcSEcCtD
Regorafenib—Abdominal pain—Epirubicin—ovarian cancer	9.35e-05	0.000623	CcSEcCtD
Regorafenib—Gastrointestinal pain—Doxorubicin—ovarian cancer	8.95e-05	0.000596	CcSEcCtD
Regorafenib—Abdominal pain—Doxorubicin—ovarian cancer	8.65e-05	0.000576	CcSEcCtD
Regorafenib—Body temperature increased—Doxorubicin—ovarian cancer	8.65e-05	0.000576	CcSEcCtD
Regorafenib—Asthenia—Epirubicin—ovarian cancer	8.49e-05	0.000565	CcSEcCtD
Regorafenib—Diarrhoea—Epirubicin—ovarian cancer	8.09e-05	0.000539	CcSEcCtD
Regorafenib—Asthenia—Doxorubicin—ovarian cancer	7.85e-05	0.000523	CcSEcCtD
Regorafenib—ABCB1—lymph node—ovarian cancer	7.65e-05	0.000547	CbGeAlD
Regorafenib—Vomiting—Epirubicin—ovarian cancer	7.52e-05	0.000501	CcSEcCtD
Regorafenib—Diarrhoea—Doxorubicin—ovarian cancer	7.49e-05	0.000499	CcSEcCtD
Regorafenib—Rash—Epirubicin—ovarian cancer	7.46e-05	0.000497	CcSEcCtD
Regorafenib—Dermatitis—Epirubicin—ovarian cancer	7.45e-05	0.000496	CcSEcCtD
Regorafenib—Headache—Epirubicin—ovarian cancer	7.41e-05	0.000493	CcSEcCtD
Regorafenib—Nausea—Epirubicin—ovarian cancer	7.02e-05	0.000468	CcSEcCtD
Regorafenib—Vomiting—Doxorubicin—ovarian cancer	6.96e-05	0.000463	CcSEcCtD
Regorafenib—Rash—Doxorubicin—ovarian cancer	6.9e-05	0.000459	CcSEcCtD
Regorafenib—Dermatitis—Doxorubicin—ovarian cancer	6.89e-05	0.000459	CcSEcCtD
Regorafenib—Headache—Doxorubicin—ovarian cancer	6.86e-05	0.000457	CcSEcCtD
Regorafenib—Nausea—Doxorubicin—ovarian cancer	6.5e-05	0.000433	CcSEcCtD
Regorafenib—FGFR1—Signaling Pathways—MMP9—ovarian cancer	2.82e-06	1.14e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—PIK3CA—ovarian cancer	2.82e-06	1.14e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MMP9—ovarian cancer	2.81e-06	1.14e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—PTEN—ovarian cancer	2.8e-06	1.13e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—HRAS—ovarian cancer	2.8e-06	1.13e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CXCL8—ovarian cancer	2.8e-06	1.13e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MAPK3—ovarian cancer	2.8e-06	1.13e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—PTEN—ovarian cancer	2.79e-06	1.13e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MAPK3—ovarian cancer	2.77e-06	1.12e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—KRAS—ovarian cancer	2.76e-06	1.12e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PTEN—ovarian cancer	2.76e-06	1.12e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PTEN—ovarian cancer	2.76e-06	1.12e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—HRAS—ovarian cancer	2.75e-06	1.11e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TP53—ovarian cancer	2.75e-06	1.11e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—PIK3CA—ovarian cancer	2.75e-06	1.11e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—MAPK3—ovarian cancer	2.74e-06	1.11e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CDKN1B—ovarian cancer	2.73e-06	1.11e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MYC—ovarian cancer	2.72e-06	1.1e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ABCB1—ovarian cancer	2.72e-06	1.1e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—VEGFA—ovarian cancer	2.72e-06	1.1e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PIK3CB—ovarian cancer	2.71e-06	1.1e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL6—ovarian cancer	2.71e-06	1.1e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL6—ovarian cancer	2.7e-06	1.09e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MYC—ovarian cancer	2.7e-06	1.09e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—STAT3—ovarian cancer	2.69e-06	1.09e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—PIK3CA—ovarian cancer	2.69e-06	1.09e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—NRAS—ovarian cancer	2.68e-06	1.09e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—IL6—ovarian cancer	2.68e-06	1.09e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—PIK3CA—ovarian cancer	2.68e-06	1.09e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CASP3—ovarian cancer	2.68e-06	1.09e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—AKT1—ovarian cancer	2.68e-06	1.09e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—PIK3CA—ovarian cancer	2.68e-06	1.08e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL2—ovarian cancer	2.68e-06	1.08e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—YAP1—ovarian cancer	2.67e-06	1.08e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—AKT1—ovarian cancer	2.67e-06	1.08e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—TYMS—ovarian cancer	2.67e-06	1.08e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	2.67e-06	1.08e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—VEGFA—ovarian cancer	2.67e-06	1.08e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—KRAS—ovarian cancer	2.67e-06	1.08e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—MYC—ovarian cancer	2.66e-06	1.08e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MAPK1—ovarian cancer	2.66e-06	1.08e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—EGFR—ovarian cancer	2.66e-06	1.08e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.65e-06	1.08e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—STAT3—ovarian cancer	2.64e-06	1.07e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MAPK1—ovarian cancer	2.64e-06	1.07e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—EGFR—ovarian cancer	2.64e-06	1.07e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—NRAS—ovarian cancer	2.63e-06	1.07e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—IL6—ovarian cancer	2.63e-06	1.07e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—AKT1—ovarian cancer	2.63e-06	1.07e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—ERBB2—ovarian cancer	2.63e-06	1.07e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—HRAS—ovarian cancer	2.63e-06	1.07e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—HRAS—ovarian cancer	2.61e-06	1.06e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCND1—ovarian cancer	2.61e-06	1.06e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—MAPK1—ovarian cancer	2.61e-06	1.06e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—EGFR—ovarian cancer	2.6e-06	1.06e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—HRAS—ovarian cancer	2.6e-06	1.06e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—TYMS—ovarian cancer	2.6e-06	1.05e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—ovarian cancer	2.6e-06	1.05e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PIK3CB—ovarian cancer	2.6e-06	1.05e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MTOR—ovarian cancer	2.6e-06	1.05e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CG—ovarian cancer	2.59e-06	1.05e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CTNNB1—ovarian cancer	2.58e-06	1.05e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MAPK3—ovarian cancer	2.57e-06	1.04e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HRAS—ovarian cancer	2.54e-06	1.03e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—PIK3CA—ovarian cancer	2.54e-06	1.03e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MMP9—ovarian cancer	2.53e-06	1.03e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—VEGFA—ovarian cancer	2.53e-06	1.03e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—VEGFA—ovarian cancer	2.52e-06	1.02e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MAPK3—ovarian cancer	2.52e-06	1.02e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PTEN—ovarian cancer	2.52e-06	1.02e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL6—ovarian cancer	2.52e-06	1.02e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—KRAS—ovarian cancer	2.51e-06	1.02e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—STAT3—ovarian cancer	2.51e-06	1.02e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—NRAS—ovarian cancer	2.5e-06	1.01e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—IL6—ovarian cancer	2.5e-06	1.01e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—STAT3—ovarian cancer	2.5e-06	1.01e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MYC—ovarian cancer	2.5e-06	1.01e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—AKT1—ovarian cancer	2.5e-06	1.01e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CXCL8—ovarian cancer	2.5e-06	1.01e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—NRAS—ovarian cancer	2.49e-06	1.01e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—IL6—ovarian cancer	2.49e-06	1.01e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—AKT1—ovarian cancer	2.49e-06	1.01e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—KRAS—ovarian cancer	2.49e-06	1.01e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—HRAS—ovarian cancer	2.49e-06	1.01e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—HRAS—ovarian cancer	2.48e-06	1e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ABCB1—ovarian cancer	2.48e-06	1e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HRAS—ovarian cancer	2.48e-06	1e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—AKT1—ovarian cancer	2.47e-06	1e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—KRAS—ovarian cancer	2.46e-06	9.97e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MYC—ovarian cancer	2.45e-06	9.94e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—PIK3CA—ovarian cancer	2.45e-06	9.92e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MAPK1—ovarian cancer	2.44e-06	9.9e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—EGFR—ovarian cancer	2.44e-06	9.9e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CDKN1B—ovarian cancer	2.44e-06	9.87e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—TYMS—ovarian cancer	2.43e-06	9.85e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL6—ovarian cancer	2.43e-06	9.85e-06	CbGpPWpGaD
Regorafenib—KIT—Disease—AKT1—ovarian cancer	2.43e-06	9.84e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CAV1—ovarian cancer	2.41e-06	9.76e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MAPK1—ovarian cancer	2.4e-06	9.72e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—EGFR—ovarian cancer	2.4e-06	9.72e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MAPK3—ovarian cancer	2.39e-06	9.7e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CASP3—ovarian cancer	2.39e-06	9.68e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MAPK3—ovarian cancer	2.39e-06	9.67e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL2—ovarian cancer	2.39e-06	9.66e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL6—ovarian cancer	2.38e-06	9.63e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL6—ovarian cancer	2.37e-06	9.61e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL6—ovarian cancer	2.37e-06	9.6e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—HRAS—ovarian cancer	2.35e-06	9.51e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTEN—ovarian cancer	2.34e-06	9.48e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MYC—ovarian cancer	2.33e-06	9.43e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCND1—ovarian cancer	2.33e-06	9.42e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MYC—ovarian cancer	2.32e-06	9.41e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—AKT1—ovarian cancer	2.32e-06	9.41e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—PIK3CA—ovarian cancer	2.31e-06	9.36e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—KRAS—ovarian cancer	2.31e-06	9.35e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—AKT1—ovarian cancer	2.31e-06	9.34e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CTNNB1—ovarian cancer	2.3e-06	9.33e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.3e-06	9.32e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—AKT1—ovarian cancer	2.3e-06	9.32e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—PIK3CA—ovarian cancer	2.29e-06	9.27e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CD—ovarian cancer	2.28e-06	9.23e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MAPK1—ovarian cancer	2.28e-06	9.23e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—EGFR—ovarian cancer	2.28e-06	9.23e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—VEGFA—ovarian cancer	2.27e-06	9.21e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MAPK1—ovarian cancer	2.27e-06	9.2e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—EGFR—ovarian cancer	2.27e-06	9.2e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—KRAS—ovarian cancer	2.27e-06	9.18e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HRAS—ovarian cancer	2.27e-06	9.18e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—PIK3CA—ovarian cancer	2.26e-06	9.16e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MMP9—ovarian cancer	2.26e-06	9.14e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—STAT3—ovarian cancer	2.25e-06	9.12e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NRAS—ovarian cancer	2.25e-06	9.1e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—IL6—ovarian cancer	2.25e-06	9.1e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—AKT1—ovarian cancer	2.24e-06	9.09e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PTEN—ovarian cancer	2.24e-06	9.09e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—ovarian cancer	2.23e-06	9.05e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—ovarian cancer	2.21e-06	8.97e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—AKT1—ovarian cancer	2.19e-06	8.89e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CG—ovarian cancer	2.19e-06	8.89e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—AKT1—ovarian cancer	2.19e-06	8.87e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—AKT1—ovarian cancer	2.19e-06	8.86e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—FASN—ovarian cancer	2.18e-06	8.82e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL6—ovarian cancer	2.17e-06	8.78e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—KRAS—ovarian cancer	2.15e-06	8.71e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MAPK3—ovarian cancer	2.15e-06	8.71e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CAV1—ovarian cancer	2.15e-06	8.71e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—KRAS—ovarian cancer	2.15e-06	8.69e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SLC5A5—ovarian cancer	2.14e-06	8.68e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—HRAS—ovarian cancer	2.14e-06	8.66e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—PIK3CA—ovarian cancer	2.12e-06	8.59e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—HRAS—ovarian cancer	2.12e-06	8.58e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CAV1—ovarian cancer	2.1e-06	8.5e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MYC—ovarian cancer	2.09e-06	8.48e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—HRAS—ovarian cancer	2.09e-06	8.47e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—PIK3CA—ovarian cancer	2.08e-06	8.44e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—AKT1—ovarian cancer	2.07e-06	8.39e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SLC2A1—ovarian cancer	2.07e-06	8.38e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.05e-06	8.32e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—ovarian cancer	2.05e-06	8.31e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MAPK1—ovarian cancer	2.05e-06	8.29e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—EGFR—ovarian cancer	2.05e-06	8.29e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL6—ovarian cancer	2.05e-06	8.29e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VEGFA—ovarian cancer	2.03e-06	8.21e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL6—ovarian cancer	2.03e-06	8.21e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—ovarian cancer	2.01e-06	8.16e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—STAT3—ovarian cancer	2.01e-06	8.13e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NRAS—ovarian cancer	2e-06	8.11e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—IL6—ovarian cancer	2e-06	8.11e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—AKT1—ovarian cancer	2e-06	8.1e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CB—ovarian cancer	1.99e-06	8.04e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.98e-06	8.04e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—PIK3CA—ovarian cancer	1.98e-06	8.01e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—PIK3CA—ovarian cancer	1.97e-06	7.99e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—HRAS—ovarian cancer	1.96e-06	7.95e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CAV1—ovarian cancer	1.96e-06	7.94e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CG—ovarian cancer	1.96e-06	7.93e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PIK3CA—ovarian cancer	1.95e-06	7.88e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PIK3CA—ovarian cancer	1.95e-06	7.88e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—KRAS—ovarian cancer	1.93e-06	7.83e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CD—ovarian cancer	1.93e-06	7.81e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—HRAS—ovarian cancer	1.93e-06	7.81e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MAPK3—ovarian cancer	1.92e-06	7.77e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—ovarian cancer	1.91e-06	7.75e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CG—ovarian cancer	1.91e-06	7.74e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—ovarian cancer	1.91e-06	7.73e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—AKT1—ovarian cancer	1.89e-06	7.64e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL6—ovarian cancer	1.88e-06	7.61e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.87e-06	7.59e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—AKT1—ovarian cancer	1.87e-06	7.57e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MYC—ovarian cancer	1.86e-06	7.55e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—AKT1—ovarian cancer	1.85e-06	7.48e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL6—ovarian cancer	1.84e-06	7.47e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—HRAS—ovarian cancer	1.83e-06	7.41e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MAPK1—ovarian cancer	1.82e-06	7.39e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—EGFR—ovarian cancer	1.82e-06	7.39e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—HRAS—ovarian cancer	1.82e-06	7.39e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CG—ovarian cancer	1.79e-06	7.23e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PIK3CA—ovarian cancer	1.78e-06	7.19e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.76e-06	7.13e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL6—ovarian cancer	1.75e-06	7.09e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL6—ovarian cancer	1.75e-06	7.07e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—AKT1—ovarian cancer	1.73e-06	7.02e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KRAS—ovarian cancer	1.72e-06	6.98e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CD—ovarian cancer	1.72e-06	6.97e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—ovarian cancer	1.72e-06	6.96e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTEN—ovarian cancer	1.72e-06	6.95e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—AKT1—ovarian cancer	1.7e-06	6.89e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CB—ovarian cancer	1.68e-06	6.81e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CD—ovarian cancer	1.68e-06	6.81e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PIK3CA—ovarian cancer	1.65e-06	6.69e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—HRAS—ovarian cancer	1.64e-06	6.66e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.63e-06	6.62e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—AKT1—ovarian cancer	1.61e-06	6.54e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—AKT1—ovarian cancer	1.61e-06	6.52e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—TYMS—ovarian cancer	1.6e-06	6.5e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—AKT1—ovarian cancer	1.59e-06	6.44e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—AKT1—ovarian cancer	1.59e-06	6.44e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PIK3CA—ovarian cancer	1.58e-06	6.41e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL6—ovarian cancer	1.57e-06	6.37e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CD—ovarian cancer	1.57e-06	6.36e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—ovarian cancer	1.53e-06	6.2e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CB—ovarian cancer	1.5e-06	6.08e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—HRAS—ovarian cancer	1.46e-06	5.93e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CB—ovarian cancer	1.46e-06	5.93e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTEN—ovarian cancer	1.45e-06	5.88e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—AKT1—ovarian cancer	1.45e-06	5.88e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL6—ovarian cancer	1.4e-06	5.68e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CB—ovarian cancer	1.37e-06	5.54e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—AKT1—ovarian cancer	1.35e-06	5.46e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTEN—ovarian cancer	1.3e-06	5.25e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—AKT1—ovarian cancer	1.29e-06	5.24e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CAV1—ovarian cancer	1.29e-06	5.24e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTEN—ovarian cancer	1.27e-06	5.13e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CA—ovarian cancer	1.21e-06	4.9e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTEN—ovarian cancer	1.18e-06	4.79e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.18e-06	4.77e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.04e-06	4.19e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CA—ovarian cancer	1.02e-06	4.15e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—AKT1—ovarian cancer	9.89e-07	4.01e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CA—ovarian cancer	9.15e-07	3.71e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CB—ovarian cancer	9.02e-07	3.66e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CA—ovarian cancer	8.93e-07	3.62e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—AKT1—ovarian cancer	8.37e-07	3.39e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CA—ovarian cancer	8.34e-07	3.38e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTEN—ovarian cancer	7.8e-07	3.16e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—AKT1—ovarian cancer	7.47e-07	3.03e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—AKT1—ovarian cancer	7.29e-07	2.95e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—AKT1—ovarian cancer	6.81e-07	2.76e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CA—ovarian cancer	5.5e-07	2.23e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AKT1—ovarian cancer	4.49e-07	1.82e-06	CbGpPWpGaD
